Utilizing Shared Big Data to Identify Liver Cancer Dedifferentiation Markers.

Area of Science:

• Oncology
• Genomics
• Bioinformatics

Background:

• Cancer stem cells (CSCs) are crucial for tumor recurrence and treatment resistance.
• The potential of big data reanalysis in cancer research, especially for CSCs, remains largely untapped.
• Understanding CSC dedifferentiation is key to developing effective cancer therapies.

Purpose of the Study:

• To demonstrate the value of big data reanalysis in cancer research using liver CSCs.
• To identify novel genes involved in liver CSC dedifferentiation.
• To discover potential therapeutic targets for liver cancer.

Main Methods:

• Utilized two public single-cell RNA-sequencing (scRNA-seq) datasets of liver cancer and healthy liver cells.
• Performed big data reanalysis to compare gene expression profiles.
• Identified differentially expressed genes between liver CSCs and healthy liver cells.

Main Results:

• Identified 519 differentially expressed genes between liver CSCs and healthy liver cells.
• Discovered Msh Homeobox 2 (MSX2) as a potential novel liver CSC dedifferentiation factor.
• MSX2 was significantly upregulated (1.36-fold, p < 1E-10) in liver CSCs compared to healthy cells.

Conclusions:

• Big data reanalysis of scRNA-seq data can yield significant discoveries in cancer research.
• MSX2 is a promising candidate gene regulating liver CSC dedifferentiation.
• Further research into MSX2 could advance knowledge of CSC biology and inform new therapeutic strategies.